Beijing Gobroad Hospital

This study tests two different CAR T-cell treatments for children and young adults with B-cell acute lymphoblastic leukemia that has come back or not responded to standard therapy. One group gets a combination of two types of CAR T-cells (CD19 and CD22), while the other gets one …

This early-phase study tests whether a new treatment called BiTE-EV is safe and can help adults with relapsed or treatment-resistant acute B-cell leukemia. Only 3 participants will receive the therapy every other day for 1-2 months, followed by regular checkups. The main goals ar…

This early-stage study tests a new treatment for people with advanced multiple myeloma that has spread outside the bones. The therapy uses a patient's own immune cells, modified to attack two cancer targets (BCMA and GPRC5D) at once. The main goal is to check safety in 18 adults,…

This study is testing a new treatment using specially engineered immune cells (CAR T cells) from donated cord blood for people with severe lupus, scleroderma, or Sjogren's syndrome that hasn't improved with standard treatments. The main goal is to check if the therapy is safe and…

This early-stage study tests a two-step treatment for people with B-cell acute lymphoblastic leukemia that has returned or not responded to standard therapies. First, patients receive donor immune cells (CAR T cells) followed by a stem cell transplant, then a second dose of donor…

This study tests a special immune cell therapy called CT041 CAR-T in 20 adults with advanced stomach or gastroesophageal junction cancer. The treatment is given after standard first-line therapy to see if it can delay cancer growth. Participants receive their own immune cells tha…

This early-phase trial tests a new treatment called FL-33 CAR T for people with acute myeloid leukemia (AML) that has come back or not responded to standard therapy. The treatment uses a patient's own immune cells, modified to find and attack cancer cells with a specific marker (…

This early-stage study is testing a new treatment called CT1190B CAR-T cell therapy in 27 adults with severe lupus or sclerosis that hasn't responded to standard treatments. The therapy uses a patient's own immune cells, modified to target and calm the overactive immune system. T…

This study tests a new treatment called CD7 CAR T-cell therapy for people with T-cell cancers (leukemia or lymphoma) that have come back or not responded to standard treatments. The therapy uses a patient's own immune cells or cells from a donor, which are modified to find and at…

This study tests a new treatment using a patient's own immune cells, modified to target and destroy harmful cells in three severe autoimmune conditions: lupus nephritis, systemic sclerosis, and Sjogren's syndrome with pulmonary hypertension. About 45 adults will receive a single …

This study tests a new treatment using CD19-CAR T cells for people with severe autoimmune diseases that haven't improved with standard therapies. About 18 participants will receive the cells to see if they can safely control the disease. The goal is to reduce symptoms and manage …

This early-stage trial tests a new cell therapy that targets two proteins (BCMA and CD19) on myeloma cells. It is for people whose multiple myeloma has come back or stopped responding to treatment and has spread to other tissues. The main goal is to check the safety of this thera…

This study is testing a new treatment called STR-P004 for people with autoimmune diseases that have come back or not responded to other treatments. The main goal is to see if it is safe and to find the best dose. About 39 adults will take part, and researchers will watch for side…

This early-phase trial is testing a new treatment called TC-G203 for people with advanced solid tumors that have a specific marker (GPC3) and have not responded to standard therapies. The main goal is to find the safest dose and check for side effects. About 30 adults will take p…

This early-phase study tests a new treatment called OL-CD19-GDT, which uses specially engineered immune cells (CAR-T cells) from a healthy donor to target and destroy faulty immune cells in people with severe, treatment-resistant autoimmune diseases like systemic sclerosis and Sj…

This study tests a new treatment using a patient's own immune cells, modified to target and attack lupus-causing cells. It is for people with severe lupus that hasn't responded to standard therapies. The goal is to see if this approach can safely control the disease and reduce sy…

This study tests a new treatment called CD5 CAR T cells for people with T-cell cancers that have come back or not responded to standard therapy. The treatment uses a patient's own immune cells or cells from a donor, which are modified in a lab to better attack the cancer. The tri…

This study looks at whether adding cytokine-induced killer (CIK) cells can prevent CAR-T cells from wearing out too early in people with relapsed or refractory B-cell acute lymphoblastic leukemia. About 213 children and young adults will be randomly assigned to receive either sta…

This early-stage study tests a new treatment for adults with advanced gastrointestinal cancer that hasn't responded to standard therapies. The treatment combines a drug called XH001 with a personalized vaccine made from the patient's own tumor markers, plus immune cells trained t…

This study tests a new treatment called CD5-CAR T cell therapy for people with T-cell cancers that have come back or not responded to standard treatments. The therapy uses a patient's own or a donor's immune cells, modified to target and kill cancer cells. The trial will first fi…